Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Colorectal Neoplasms 19Carcinoma, Non-Small-Cell Lung 19Breast Neoplasms 17Lung Neoplasms 15Colonic Neoplasms 11Head and Neck Neoplasms 9Rectal Neoplasms 7Glioblastoma 5Prostatic Neoplasms 4Precancerous Conditions 4Mouth Neoplasms 4Esophageal Neoplasms 4Central Nervous System Neoplasms 4Adenomatous Polyposis Coli 4Uterine Cervical Neoplasms 3Unspecified Adult Solid Tumor, Protocol Specific 3Sarcoma 3Neuroblastoma 3Neoplasms 3Liver Neoplasms 3Gliosarcoma 3Glioma 3Urinary Bladder Neoplasms 2Triple Negative Breast Neoplasms 2Smoking 2Salivary Gland Neoplasms 2Pancreatic Neoplasms 2Oropharyngeal Neoplasms 2Nasopharyngeal Neoplasms 2Multiple Myeloma 2

Interventions

Peripheral Blood Stem Cell Transplantation 4Epoetin Alfa 3Darbepoetin alfa 3Cyclophosphamide 3liposomal amphotericin B 2fludarabine phosphate 2Microarray Analysis 2Methylprednisolone 2Interferon-alpha 2In Situ Hybridization, Fluorescence 2Filgrastim 2Cytogenetic Analysis 2Cyclosporine 2Caspofungin 2Bortezomib 2Antilymphocyte Serum 2tanespimycin 1siltuximab 1pyroxamide 1piperine 1ibrutinib 1ferrous sulfate 1ferric gluconate 1aldesleukin 1Whole-Body Irradiation 1Watchful Waiting 1Urination 1Topotecan 1Therapeutics 1Tacrolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Monoclonal Gammopathy of Undetermined Significance × Celecoxib × Clear all
NCT00099047 2016-12-30

Celecoxib in Preventing Multiple Myeloma in Patients With Monoclonal Gammopathy or Smoldering Myeloma

National Cancer Institute (NCI)

Phase 2 Completed
23 enrolled 7 charts
Plasma cell

Smoldering Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡